Proinsulin to C-Peptide Ratio in the First Year After Diagnosis of Type 1 Diabetes.

What Was Tested

Researchers studied C-Peptide in this randomized controlled trial publication.

The proinsulin to C-peptide (PI:C) ratio is reputedly a biomarker of β-cell endoplasmic reticulum (ER) stress.

This study examined the natural history of the PI:C ratio and its correlation with residual β-cell function in childhood new-onset type 1 diabetes (T1D).

Over the first year of T1D, the temporal trend in fasting and nutrient-stimulated PI data is limited.

Who Took Part

The abstract describes 99 participants taking part.

PubMed indexes the participants as young children, children and teenagers, both men and women.

Of the 99 participants in the primary study, aged 4 to 18 years, 30 were placebo.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this C-Peptide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on C-Peptide, so expectations could not easily colour the readings.

Some participants received a placebo instead of C-Peptide, giving a reference point.

PI was a secondary pre-planned analysis of their 1-year, randomized, double-blind, placebo-controlled gamma aminobutyric acid (GABA) trial in new-onset T1D.

A liquid mixed meal tolerance test was administered at baseline and 5 and 12 months for determination of C-peptide, PI, glucose, and hemoglobin A1C.

What Was Measured

The subject headings attached to it are Biomarkers, C-Peptide, Diabetes Mellitus, Type 1, Endoplasmic Reticulum Stress, Fasting, Glucose Tolerance Test and Glycemic Control.

The authors tagged it with the keywords children, proinsulin to C-peptide ratio and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of C-Peptide in 99 participants.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the C-Peptide compound page, all human trials.